Clinical Trial

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-02.
Status change: Not Yet Recruiting → Recruiting 2023-03-02
Trial Details
NCT Number NCT05753566
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Prostate Cancer, Biochemical Recurrence
Enrollment 96 participants
Start Date 2023-03
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2023-03-06